AXON ENTERPRISE, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - continued (in thousands, except per share amounts) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| THREE MONTHS ENDED |
| |||||||
|
| 31 MAR 2024 |
| 31 DEC 2023 |
| 31 MAR 2023 |
| |||
Non-GAAP net income: |
|
|
|
|
|
|
|
|
|
|
GAAP net income |
| $ | 133,218 |
| $ | 57,271 |
| $ | 45,139 |
|
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
| 75,115 |
|
| 35,130 |
|
| 34,350 |
|
Unrealized gain on strategic investments and marketable securities, net |
|
| (97,419) |
|
| (521) |
|
| (15,570) |
|
Gain on remeasurement of previously held minority interest, net |
|
| (42,292) |
|
| — |
|
| — |
|
Transaction costs related to strategic investments and acquisitions |
|
| 6,357 |
|
| 2,708 |
|
| 843 |
|
Loss on disposal, abandonment, and impairment of property, equipment and intangible assets, net |
|
| — |
|
| — |
|
| 156 |
|
Costs related to antitrust and FTC litigations |
|
| 224 |
|
| 169 |
|
| — |
|
Payroll taxes related to XSPP vesting and CEO Award option exercises |
|
| — |
|
| 50 |
|
| 6,392 |
|
Income tax effects |
|
| 13,647 |
|
| (9,391) |
|
| (6,660) |
|
Non-GAAP net income |
| $ | 88,850 |
| $ | 85,416 |
| $ | 64,650 |
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income per common share |
|
|
|
|
|
|
|
|
|
|
GAAP |
| $ | 1.73 |
| $ | 0.75 |
| $ | 0.61 |
|
Non-GAAP |
| $ | 1.15 |
| $ | 1.12 |
| $ | 0.88 |
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of diluted common and common equivalent shares outstanding (in thousands) |
|
| 77,132 |
|
| 76,178 |
|
| 73,880 |
|
Axon reports Q1 2024 revenue of $461 million, up 34% year over year, raises outlook
| | More GIS News |
|
RELATED NEWS